The Latest Cardiac and Vascular News
First-quarter revenue of $3.65 billion decreased 2% on a reported basis and increased 2% on a constant currency basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.09; Adjusted EPS totaled $0.59 Baxter expects full-year 2023 sales growth of 1% […]
Fourth-quarter sales of $3.9 billion increased 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) of $0.36 and adjusted diluted EPS of $0.88 Full-year […]
Third-quarter revenue of $3.8 billion increased 17% on a reported basis, 23% on a constant currency basis and rose slightly on an operational basis1 Third-quarter U.S. GAAP earnings (loss) per share (EPS) were ($5.83); Adjusted EPS totaled $0.82 Third-quarter results […]
First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93 Baxter expects full-year 2022 […]
Findings suggest that monitoring changes in stroke volume and cardiac output could help predict mortality in critically ill patients Baxter-sponsored symposium advances expert dialogue on fluid management DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a leader in patient monitoring, physical assessment […]
First and only manufacturer-prepared premix formulation of norepinephrine available Offers variety of storage options under refrigeration and at room temperature, allowing drug to be placed closer to patient care settings Ready-to-use format means less chance of compounding errors and touch […]
ATLANTA, July 29, 2021 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. (“Baxter”) (NYSE: BAX ), for […]
Large, multicenter, retrospective study of Colombian dialysis patients indicates cardiovascular events were 35% lower for patients on HDx therapy enabled by Theranova than participants on standard hemodialysis1 Data from study also show HDx therapy may reduce hospitalization rates up to 18%1 DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter […]
